In a study by Liu et al., NF1 mutations were associated with improved survival in patients receiving immunotherapy, but with poorer outcomes under targeted therapies for patients with EGFR-mutated or ALK-rearranged NSCLC (21). Here, EGFR is linked to non-small cell lung carcinoma.